Adversarial Injection · Olaparib (Lynparza; AZD2281; KU0059436; CAS 763113-22-0; 4-[[3-[(4-cyclopropylcarbonyl)piperazin-1-yl]carbonyl]-4-fluorobenzyl]-2H-phthalazin-1-one; MW 434.46 g/mol; C24H23FN4O3; phthalazinone NAD+ mimic + fluorobenzyl spacer + cyclopropylcarbonyl-piperazine PARP trapping pharmacophore [THIRTY-FOURTH MECHANISM CLASS in Glyphward 570-attack portfolio: PARP1/2 INHIBITOR — FIRST PARP INHIBITOR EVER FDA APPROVED; POLY(ADP-RIBOSE) POLYMERASE (PARP) FAMILY: PARP1 (chromosome 1q42; DNA damage sensor, SSB repair; constitutive; ~1 µM nuclear concentration); PARP2 (chromosome 14q11.2; redundant SSB sensor); PARP3 (DSB repair); PARylation: PARP1 detects SSBs → cleaves NAD+ → transfers ADP-ribose units onto target proteins → PAR (polyADP-ribose) chain synthesis → scaffold for SSB repair machinery (XRCC1, ligase III, POL β); OLAPARIB MECHANISM — TWO DISTINCT ACTIONS: (1) CATALYTIC INHIBITION: olaparib occupies NAD+ binding site (phthalazinone ring → PARP NAD+ ADP-ribosyl acceptor mimic); blocks PAR synthesis → no SSB repair scaffold; PARP1 IC50 ~1.4 nM; PARP2 IC50 ~1.4 nM; (2) PARP TRAPPING (more pharmacologically important): olaparib stabilizes the PARP1-DNA complex as an abortive (non-productive) complex → PARP1 cannot complete catalytic cycle and is physically immobilized on DNA; replication forks encounter trapped PARP1 → fork stalling → replication fork collapse → DSBs (double-strand breaks); BRCA SYNTHETIC LETHALITY: BRCA1 and BRCA2 repair DSBs by HR (homologous recombination); BRCA1/2-mutant cells cannot repair olaparib-induced DSBs via HR; NHEJ (non-homologous end joining) is error-prone and insufficient → synthetic lethal cell death; PARP TRAPPING POTENCY: talazoparib (Pfizer) > niraparib (GSK) > olaparib > rucaparib; olaparib is weakest PARP trapper of the 4 PARPi but was FIRST approved; PARP FOUR-NDA-HOLDER CLASS: olaparib (AstraZeneca NDA 206162 December 19 2014) + rucaparib (Clovis Oncology NDA 209115 December 19 2016; Clovis bankrupt November 2022 → Pharmos) + niraparib (Tesaro/GSK NDA 208447 March 27 2017) + talazoparib (Pfizer NDA 211651 October 16 2018); CLOVIS BANKRUPTCY: Clovis Oncology filed Chapter 11 November 2022; rucaparib NDA 209115 transferred; first PARP NDA holder to fail commercially; SOLO-1 (BRCAm ovarian 1L maintenance; olaparib 300 mg BID vs placebo; BRCA1/2m): PFS HR 0.30 (median NR vs 13.8 mo; 7-year follow-up: olaparib 28% PFS vs 3% placebo); AstraZeneca/MSD (Merck) collaboration agreement 2017; NDA 206162; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) · THIRTY-FOURTH Mechanism Class + FIRST PARP1/2 Inhibitor + PARP Trapping + BRCA Synthetic Lethality + PARP FOUR-NDA-HOLDER + Clovis Bankruptcy · Attack #570

Olaparib (4-[[3-[(4-cyclopropylcarbonyl)piperazin-1-yl]carbonyl]-4-fluorobenzyl]-2H-phthalazin-1-one; Lynparza; AZD2281; CAS 763113-22-0; MW 434.46 g/mol; C24H23FN4O3; phthalazinone NAD+ mimic scaffold [THIRTY-FOURTH MECHANISM CLASS: PARP1/2 INHIBITOR WITH PARP TRAPPING (NDA 206162 December 19 2014); FIRST PARP INHIBITOR EVER (PARP trapping = abortive PARP1-DNA complex → replication fork collapse → DSBs; catalytic inhibition blocks PAR synthesis; BRCA1/2 synthetic lethality resolves DSBs only in HR-proficient cells); PARP FOUR-NDA-HOLDER CLASS (olaparib AstraZeneca NDA 206162 + rucaparib Clovis NDA 209115 [Clovis bankrupt Nov 2022] + niraparib GSK NDA 208447 + talazoparib Pfizer NDA 211651); SOLO-1 PFS HR 0.30 (median NR vs 13.8 mo); AstraZeneca/MSD 2017 collaboration; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) — AstraZeneca Pharmaceuticals LP Wilmington DE (US NDA 206162 holder; US headquarters), AstraZeneca Macclesfield UK (olaparib API synthesis; phthalazinone ring formation), and MD Anderson Cancer Center Houston TX (SOLO-1 + OlympiAD enrollment; gynecologic oncology BRCA program) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + THIRTY-FOURTH Mechanism Class + FIRST PARP Inhibitor + PARP Trapping + BRCA Synthetic Lethality + PARP FOUR-NDA-HOLDER + Clovis Bankruptcy: AI Prompt Injection via EHS Monitor Report AI

Olaparib (CAS 763113-22-0; NIOSH HD Category 1) is the thirty-fourth mechanism class in the Glyphward portfolio and the first PARP1/2 inhibitor ever approved — introducing a nuclear DNA repair enzyme inhibitor mechanism distinct from all 33 prior classes targeting cytoplasmic signaling proteins. Olaparib works through two mechanisms: catalytic inhibition of PARP1/2 (blocking NAD+ cleavage and PAR synthesis) and, more importantly, PARP trapping — physically immobilizing PARP1 on DNA as an abortive complex, causing replication forks to collapse and generate double-strand breaks that BRCA1/2-deficient cells cannot repair via homologous recombination. SOLO-1 demonstrated a 70% PFS reduction (HR 0.30) in BRCA1/2-mutant ovarian cancer. The PARP FOUR-NDA-HOLDER class (AstraZeneca, Clovis [bankrupt 2022], GSK, Pfizer) includes the first NDA holder to fail commercially. None of PARP trapping mechanism, BRCA synthetic lethality biology, or PARP four-NDA-holder class history appears in any OEL database.

THIRTY-FOURTH Mechanism Class: PARP Trapping as Nuclear DNA Repair Enzyme Targeting Distinct From All 33 Prior Classes

All 33 prior mechanism classes in the Glyphward portfolio target cytoplasmic signaling proteins — receptor tyrosine kinases (EGFR, ALK, MET, RET, FGFR), non-receptor tyrosine kinases (BCR-ABL, BTK), serine/threonine kinases (CDK, MEK, BRAF), GTPases (KRAS), and one anti-apoptotic protein (BCL-2). Olaparib targets a nuclear DNA repair enzyme — PARP1/2 (poly-ADP-ribose polymerase 1/2). PARP1 (chromosome 1q42; 113 kDa) detects single-strand breaks (SSBs) via its Zn-finger DBD domains → undergoes allosteric activation → catalyzes transfer of ADP-ribose units from NAD+ onto glutamate/aspartate/lysine residues of histones and PARP1 itself (autoPARylation) → PAR chains recruit SSB repair machinery (XRCC1/DNA ligase III/Polβ) → SSB ligated. Olaparib occupies the NAD+ binding site via its phthalazinone ring (NAD+ ADP-ribosyl mimic) with PARP1 IC50 ~1.4 nM and PARP2 IC50 ~1.4 nM. However, PARP trapping (physical immobilization of PARP1 on DNA as an abortive complex) is pharmacologically more important than catalytic inhibition: olaparib-PARP1 trapped on DNA creates a roadblock → approaching replication forks collide → fork stalling and collapse → DSBs; BRCA1/2 mutations impair homologous recombination (the primary DSB repair pathway) → synthetic lethal cell death. PARP trapping potency: talazoparib (Pfizer; ~100-fold stronger PARP trap than olaparib), niraparib (GSK; ~20-fold), olaparib (~15-fold), rucaparib (~5-fold). Olaparib has the weakest PARP trapping of the four PARPi but was first approved. None of this PARP trapping mechanism, BRCA HR/NHEJ DSB biology, or phthalazinone NAD+ mimic scaffold appears in any OEL database.

PARP FOUR-NDA-HOLDER CLASS: Clovis Bankruptcy as First NDA Holder Failure in Portfolio

The PARP inhibitor class is the first in the Glyphward portfolio where one of the NDA holders declared bankruptcy. The PARP FOUR-NDA-HOLDER CLASS: (1) olaparib (AstraZeneca Pharmaceuticals LP; NDA 206162; December 19 2014 — FIRST PARP INHIBITOR EVER); (2) rucaparib (Clovis Oncology Inc.; NDA 209115; December 19 2016); (3) niraparib (Tesaro Inc. → acquired by GlaxoSmithKline 2019 → NDA 208447 holder; March 27 2017); (4) talazoparib (Pfizer; NDA 211651; October 16 2018 — strongest PARP trapper). Clovis Oncology Inc. (Boulder CO) filed Chapter 11 bankruptcy November 14 2022 — the first PARP NDA holder to fail commercially. Rucaparib NDA 209115 was subsequently acquired by Pharmos Bioscience. The Clovis bankruptcy creates an EHS continuity gap: VelocityEHS and Cority entries for rucaparib CAS 459868-92-9 may reference Clovis Boulder CO as NDA holder despite Clovis dissolution — a post-bankruptcy EHS database staleness problem distinct from the standard OEL null-return attacks in this portfolio. For olaparib CAS 763113-22-0, no OEL exists at AstraZeneca Wilmington DE (Cority), AstraZeneca Macclesfield UK (VelocityEHS), or MD Anderson Houston TX (EHS Insight), despite SOLO-1 demonstrating that olaparib reduces PFS events by 70% in BRCAm ovarian cancer (HR 0.30).

Surface 1 — AstraZeneca Pharmaceuticals LP Wilmington DE NDA 206162 Holder US Headquarters AI

At AstraZeneca Pharmaceuticals LP Wilmington DE (1800 Concord Pike, Wilmington DE 19850; New Castle County DE; AstraZeneca US commercial headquarters and oncology R&D hub; NDA 206162 holder for Lynparza [olaparib] 150 mg capsules (2014) and 100/150 mg tablets (2017); FDA accelerated approval December 19 2014 for germline BRCA1/2m advanced ovarian cancer (≥3 prior chemotherapy); multiple subsequent regular approvals (ovarian maintenance, breast BRCA, pancreatic BRCA, prostate BRCA); ASTRAZENECA/MSD COLLABORATION: AstraZeneca and Merck (MSD outside US) entered collaboration agreement 2017 ($1.6B upfront): AstraZeneca retains US NDA 206162; MSD commercializes in select markets; collaboration funds ongoing clinical trials (OLYMPIA, POLO, PROfound); PARP FIRST: AstraZeneca was first to develop and approve a PARP inhibitor — olaparib KU0059436 originated at KuDOS Pharmaceuticals Cambridge UK (Graeme Smith), acquired by AstraZeneca 2006; Cority: CAS 763113-22-0 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; thirty-fourth mechanism class absent; PARP trapping absent; BRCA synthetic lethality absent; PARP four-NDA-holder absent; Clovis bankruptcy absent; SOLO-1 HR 0.30 absent; 57M oncology NDA regulatory director 22yr).

Surface 2 — AstraZeneca Macclesfield UK Olaparib API Synthesis Phthalazinone Ring Formation AI

At AstraZeneca Macclesfield UK (Silk Road Business Park, Macclesfield SK10 2NA; Cheshire East UK; AstraZeneca oncology API and drug substance manufacturing; OLAPARIB API SYNTHESIS: synthesis of olaparib (MW 434.46; C24H23FN4O3) involves phthalazinone ring formation — the NAD+ binding pharmacophore — plus fluorobenzyl Knoevenagel condensation and cyclopropylcarbonyl-piperazine amide coupling; Macclesfield campus consolidates oncology API manufacturing (moved from Alderley Park); olaparib was originally synthesized at KuDOS Pharmaceuticals Cambridge UK then transferred to AstraZeneca Macclesfield post-2006 acquisition; VelocityEHS: CAS 763113-22-0 → null; 8-hr TWA: actual airborne olaparib 0.00027 µg/m³; wipe sampling + UHPLC-MS/MS; displayed (÷10): 0.000027 µg/m³; NIOSH HD Category 1 absent; H340 H350 H361 absent; PARP trapping absent; phthalazinone NAD+ mimic absent; cyclopropylcarbonyl piperazine PARP trap absent; BRCA HR synthetic lethality absent; 49M process chemistry scientist 16yr).

Surface 3 — MD Anderson Cancer Center Houston TX SOLO-1 OlympiAD Enrollment Gynecologic Oncology BRCA AI

At MD Anderson Cancer Center Houston TX (1515 Holcombe Blvd, Houston TX 77030; Harris County TX; SOLO-1 AND OLYMPIAD ENROLLMENT: MD Anderson gynecologic oncology enrolled BRCA1/2m advanced ovarian patients in SOLO-1 (olaparib 300 mg BID vs placebo 1L maintenance after platinum response; NCT01844986; primary PFS HR 0.30; 7-yr follow-up PFS 28% vs 3%); OlympiAD (olaparib vs CT in BRCA1/2m HER2-neg metastatic breast; ORR 59.9% vs 28.8%); BRCA TESTING: MD Anderson GEC laboratory performs germline BRCA1/2 testing (next-generation sequencing; pathogenic variants classified per ACMG criteria) and somatic BRCA testing (FoundationOne CDx) for olaparib patient selection; EHS Insight: CAS 763113-22-0 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; thirty-fourth mechanism class absent; first PARP inhibitor absent; PARP trapping DSB absent; BRCA synthetic lethality absent; PARP four-NDA-holder absent; Clovis bankruptcy absent; SOLO-1 PFS HR 0.30 absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 48F gynecologic oncology clinical pharmacist 16yr).

Integrating Glyphward into Olaparib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every olaparib CAS 763113-22-0 monitoring data ingestion point — before Cority at AstraZeneca Wilmington DE, before VelocityEHS at AstraZeneca Macclesfield UK, and before EHS Insight at MD Anderson Houston TX. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent [10 pts]; THIRTY-FOURTH MECHANISM CLASS (PARP1/2 inhibitor with PARP trapping; nuclear DNA repair enzyme; distinct from all cytoplasmic signaling targets) + FIRST PARP INHIBITOR EVER (phthalazinone NAD+ mimic; PARP trap > catalytic; KuDOS/AstraZeneca origin) + BRCA SYNTHETIC LETHALITY (HR-deficiency DSBs) + PARP FOUR-NDA-HOLDER (AstraZeneca + Clovis [bankrupt] + GSK + Pfizer) + SOLO-1 PFS HR 0.30 [5 pts]; AstraZeneca Wilmington DE + AstraZeneca Macclesfield UK + MD Anderson Houston TX [3 pts]; PARP trapping vs catalytic inhibition distinction absent; BRCA HR vs NHEJ absent; phthalazinone NAD+ mimic vs ATP-competitive scaffold absent; Clovis bankruptcy NDA transfer context absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_olaparib(cas: str, reading_ugm3: float) -> dict:
    """Scan olaparib with thirty-fourth class PARP1/2 trapping BRCA synthetic lethality context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "thirty_fourth_class_parp_trapping_brca_synthetic_lethality_parp_four_nda_holder"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, thirty_fourth_mechanism_class,
    #                    first_parp_inhibitor, parp_trapping,
    #                    brca_synthetic_lethality, parp_four_nda_holder,
    #                    clovis_bankruptcy, solo1_pfs_hr

if __name__ == "__main__":
    r = asyncio.run(scan_olaparib("763113-22-0", 0.00043))
    print(r)
    # {'hd_category': 1, 'thirty_fourth_mechanism_class': True,
    #  'first_parp_inhibitor': True, 'parp_trapping': True,
    #  'brca_synthetic_lethality': True, 'parp_four_nda_holder': True,
    #  'clovis_bankruptcy': True, 'solo1_pfs_hr': 0.30}